Over the past 5 years KBP Biosciences has been steadily growing up its pipeline of new drugs from its base in China. But this morning the biotech company is unveiling a dramatic change of scene, with plans to set up a global headquarters in Philadelphia while taking the wraps off a $76 million venture round that will give its new American CEO the cash to make a splash at the FDA.
Pernix` Treximet Receives Supplemental Approval in US For Migraine
Pernix Figures 1 + 1 + 1 Equals More Than Three with New Zohydro Salesforce
Zogenix Jettisons Controversial Pain Med Zohydro for $100M-Plus